Dexamethasone reduces IL-17 and Tim-3 expression in BALF of asthmatic mice

Abstract

This study investigated the expression of interleukin-17 (IL-17) and T cell immunoglobulin mucin and domain-containing molecule-3 (Tim-3) in bronchoalveolar lavage fluid (BALF) of asthmatic mice and the effect of dexamethasone (DEX) on these factors. Thirty-six mice were randomly divided into three groups: normal group, asthmatic group and DEX group. The mouse model of asthma was established by sensitization with ovalbumin in both the asthmatic and DEX groups. The levels of IL-6, IL-10, IL-17 and TGF-β were measured in BALF by enzyme-linked immunesorbent assay (ELISA). The mRNA expression level of Tim-3 was detected by reverse transcription polymerase chain reaction (RT-PCR). The ratio of Tim-3+CD4+ cells to total CD4+ cells in BALF was determined by flow cytometry. Differential inflammatory cells in BALF were detected. The correlations among IL-17, IL-6, IL-10, Tim-3 and inflammatory cells were analyzed. The results showed that the levels of IL-17, IL-6 and Tim-3 were substantially increased and the IL-10 level decreased in BALF in the asthmatic mice, which was significantly reversed by DEX treatment. IL-17 expression was positively correlated with IL-6 and Tim-3 expression and the number of inflammatory cells but negatively with IL-10 expression. These results indicate that the increased expression of IL-17 and Tim-3 in BALF may be implicated in the occurrence and development of asthmatic inflammation; the mechanism by which DEX suppresses asthmatic airway inflammation involves down-regulation of IL-17 and Tim-3 levels.

Keywords

asthma / Th17 cells / Tim-3 / cytokines / corticosteroids

References

[1] ZhuJ, YamaneH, PaulWE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol, 2010, 28: 445-489

[2] BettelliE, KornT, KuchrooVK. Th17: The third member of the effector T cell trilogy. Curr Opin Immunol, 2007, 19(6): 652-657

[3] BettelliE, KornT, OukkaM, et al.. Induction and effector functions of T (H) 17 cells. Nature, 2008, 453: 1051-1057

[4] ObokiK, OhnoT, SaitoH T, et al.. h17 and allergy. Allerqol Int, 2008, 57(2): 121-134

[5] SunYC, ZhouQT, YaoWZ. Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma. Chin Med J, 2005, 118(11): 953-956

[6] WangYH, LiuYJ. The IL-17 cytokine family and their role in allergic inflammation. Current Opinion Immunol, 2008, 20(6): 697-702

[7] ChakirJ, ShannonJ, MoletS, et al.. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol, 2003, 111(6): 1293-1298

[8] HellingsPW, KasranA, LiuZ, et al.. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol, 2003, 28(1): 42-50

[9] OdaN, CanelosPB, EssayanDM, et al.. Interleukin-17F induces pulmonary neutrophilia and amplifies antigen induced allergic response. Am J Respir Crit Care Med, 2005, 171(1): 12-18

[10] NakaeS, KomiyamaY, NambuA, et al.. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity, 2002, 17(3): 375-387

[11] Wills-KarpM, BelkaidY, KarpCL. I-Tim-izing the pathways of counter-regulation. Nat Immunol, 2003, 4(11): 1050-1052

[12] KuchrooVK, UmetsuDT, DekruyffRH, et al.. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol, 2003, 3(6): 454-462

[13] HastingsWD, AndersonDE, KassamN, et al.. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol, 2009, 39(9): 2492-2501

[14] WangF, WanL, ZhangC, et al.. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology, 2009, 21(5): 342-349

[15] ChenY, LangrishCL, MckenzieB, et al.. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest, 2006, 116(5): 1317-1326

[16] NiwaH, SatohT, MatsushimaY, et al.. Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clin Immunol, 2009, 132(2): 184-194

[17] SekiM, OomizuS, SakataKM, et al.. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol, 2008, 127(1): 78-88

[18] StampfliMR, WileyRE, NeighGS, et al.. GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice. J Clin Invest, 1998, 102(9): 1704-1714

[19] YokoyamaA, HamazakiT, OhshitaA, et al.. Effect of aerosolized docosahexaenoic acid in a mouse model of atopic asthma. Int Arch Allergy Immunol, 2000, 123(4): 327-332

[20] ChaeWJ, LeeHK, HanJH, et al.. Qualitatively differential regulation of T cell activation and apoptosis by T cell receptor zeta chain ITAMs and their tyrosine residues. Int Immunol, 2004, 16(9): 1225-1236

[21] BraunCM, HuangSK, BashianGG, et al.. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol, 1997, 100(3): 400-407

[22] MonneyL, SabatosCA, GaqliaJL, et al.. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002, 415(6871): 536-541

[23] Sanchez-FueyoA, TianJ, PicarellaD, et al.. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol, 2003, 4(11): 1093-1101

[24] NakaeS, IwakuraY, SutoH, et al.. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol, 2007, 81(5): 1258-1268

[25] MaddoxL, SchwartzDA. The pathophysiology of asthma. Annu Rev Med, 2002, 53: 477-498

[26] WalkerC, BodeE, BoerL, et al.. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis, 1992, 146(1): 109-115

[27] RobinsonDS, HamidQ, YingS, et al.. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326(5): 298-304

[28] McHughSM, DeightonJ, StewartAG, et al.. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy, 1995, 25(9): 828-838

[29] RutkowskiR, MoniuszkoT, Stasiak-BarmutaA, et al.. CD80 and CD86 expression on LPS-stimulated monocytes and the effect of CD80 and CD86 blockade on IL-4 and IFN-gamma production in nonatopic bronchial asthma. Arch Immunol Ther Exp, 2003, 51(6): 421-428

[30] PappuBP, AnqkasekwinaiP, DongC. Regulatory mechanisms of helper T cell differentiation: New lessons learned from interleukin 17 family cytokines. Pharmacol Ther, 2008, 117(3): 374-384

[31] WakashinH, HiroseK, MaezawaY, et al.. IL-23 and Th17 cells enhance Th2-Cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med, 2008, 10: 1023-1032

[32] CheungPF, WongCK, LamCW. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes mediated allergic inflammation. J Immunol, 2008, 180(8): 5625-5635

[33] HuWK, LuXX, YangS, et al.. Expression of the Th1-specific cell-surface protein Tim-3 increases in a murine model of atopic asthma. J Asthma, 2009, 46(9): 872-877

[34] KamimuraD, IshiharaK, HiranoT. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem pharmacol, 2003, 149: 1-38

[35] BettelliE, CarrierY, GaoW, et al.. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, 441(7090): 235-238

[36] ManqanPR, HarringtonLE, O’QuinnDB, et al.. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature, 2006, 441(7090): 231-234

[37] VignolaAM, ChanezP, ChiapparaG, et al.. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med, 1997, 156: 591-599

[38] HoshinoM, NakamuraY, SimJJ. Expression of growth factors and remodeling of the airway wall in bronchial asthma. Thorax, 1998, 53(1): 21-27

[39] MinshallEM, LeungDY, MartinRJ, et al.. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol, 1997, 17(3): 326-333